York Pharma completes acquisition from Solvay

York Pharmahas completed its €28.5 million acquisition of the dermatological and wound care products Flammazine and Flammacerium from[C#198600973:Solvay] Pharmaceuticals. [C#198600973:Solvay] will receive €17 million up-front and an additional €11.5 million by the end of the year. Flammazine and Flammacerium, both of which contain silver sulfadiazine, are sold in 21 countries and have annual sales of around £8.5 million.

York Pharmahas completed its €28.5 million acquisition of the dermatological and wound care products Flammazine and Flammacerium fromSolvay Pharmaceuticals. Solvay will receive €17 million up-front and an additional €11.5 million by the end of the year. Flammazine and Flammacerium, both of which contain silver sulfadiazine, are sold in 21 countries and have annual sales of around £8.5 million.

More from Dermatological

More from Therapeutic Category

BMS’s Reblozyl Misses Primary Endpoint In Myelofibrosis Anemia

 

The drugmaker announced topline results from the Phase III INDEPENDENCE trial, which did meet key secondary endpoints.

Insmed’s New R&D Site Focused On ‘Synthetic Rescue’

 

A new small-molecule approach to turning on beneficial genes to counteract disease-causing mutations is being pioneered by Insmed’s UK-based scientists.

AI-First, Big Pharma, Chinese Firms In Race - What’s Ahead For PRMT5 Inhibitors

 
• By 

As AI-driven firms including Insilico, big pharmas J&J, Amgen, GSK and AstraZeneca and Chinese and Indian firms like BeOne and Dr. Reddy’s advance PRMT5 inhibitor candidates, what’s driving interest, what could lead to the first global approval and what are the challenges ahead?